| Full Name | Kim Kurak |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 420 Grove St, Brandon, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023041431 | NPI | - | NPPES |
| 1011619 | Medicaid | VT | |
| NX4659 | Other | VT | PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 032-000525 (Vermont) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vna & Hospice Of The Southwest Region Inc | Rutland, VT | Home health agency |
| Addison County Home Health & Hospice Inc | Middlebury, VT | Home health agency |
| Rutland Regional Medical Center | Rutland, VT | Hospital |
| Porter Hospital, Inc | Middlebury, VT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Health Centers Of The Rutland Region Inc | 2961467386 | 85 |
News Archive
ImmunoGen, Inc. today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.
Duke Medicine researchers have shown how gene mutations may cause common forms of cartilage tumors. In a study published in the Feb. 16, 2015, issue of the Proceedings of the National Academy of Sciences, Duke researchers and their colleagues revealed that mutations in the isocitrate dehydrogenase (IDH) gene contribute to the formation of benign tumors in cartilage that can be a precursor to malignancies.
Deadly and difficult to treat, liver cancer has long resisted attempts by researchers to develop ways to prolong life and prevent recurrence.
This post on the Center for Strategic and International Studies's Commission on Smart Global Health Policy blog examines tuberculosis (TB) in South Africa, "which has the highest tuberculosis infection rate per population and accounts for 5 percent of the global TB burden."
InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.
› Verified 8 days ago
| Entity Name | Community Health Centers Of The Rutland Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336193838 PECOS PAC ID: 2961467386 Enrollment ID: O20041129000357 |
News Archive
ImmunoGen, Inc. today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.
Duke Medicine researchers have shown how gene mutations may cause common forms of cartilage tumors. In a study published in the Feb. 16, 2015, issue of the Proceedings of the National Academy of Sciences, Duke researchers and their colleagues revealed that mutations in the isocitrate dehydrogenase (IDH) gene contribute to the formation of benign tumors in cartilage that can be a precursor to malignancies.
Deadly and difficult to treat, liver cancer has long resisted attempts by researchers to develop ways to prolong life and prevent recurrence.
This post on the Center for Strategic and International Studies's Commission on Smart Global Health Policy blog examines tuberculosis (TB) in South Africa, "which has the highest tuberculosis infection rate per population and accounts for 5 percent of the global TB burden."
InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.
› Verified 8 days ago
| Entity Name | Community Health Centers Of The Rutland Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073567590 PECOS PAC ID: 2961467386 Enrollment ID: O20041129000784 |
News Archive
ImmunoGen, Inc. today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.
Duke Medicine researchers have shown how gene mutations may cause common forms of cartilage tumors. In a study published in the Feb. 16, 2015, issue of the Proceedings of the National Academy of Sciences, Duke researchers and their colleagues revealed that mutations in the isocitrate dehydrogenase (IDH) gene contribute to the formation of benign tumors in cartilage that can be a precursor to malignancies.
Deadly and difficult to treat, liver cancer has long resisted attempts by researchers to develop ways to prolong life and prevent recurrence.
This post on the Center for Strategic and International Studies's Commission on Smart Global Health Policy blog examines tuberculosis (TB) in South Africa, "which has the highest tuberculosis infection rate per population and accounts for 5 percent of the global TB burden."
InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.
› Verified 8 days ago
| Entity Name | Community Health Centers Of The Rutland Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104870922 PECOS PAC ID: 2961467386 Enrollment ID: O20050131001023 |
News Archive
ImmunoGen, Inc. today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.
Duke Medicine researchers have shown how gene mutations may cause common forms of cartilage tumors. In a study published in the Feb. 16, 2015, issue of the Proceedings of the National Academy of Sciences, Duke researchers and their colleagues revealed that mutations in the isocitrate dehydrogenase (IDH) gene contribute to the formation of benign tumors in cartilage that can be a precursor to malignancies.
Deadly and difficult to treat, liver cancer has long resisted attempts by researchers to develop ways to prolong life and prevent recurrence.
This post on the Center for Strategic and International Studies's Commission on Smart Global Health Policy blog examines tuberculosis (TB) in South Africa, "which has the highest tuberculosis infection rate per population and accounts for 5 percent of the global TB burden."
InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.
› Verified 8 days ago
| Entity Name | Community Health Centers Of The Rutland Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467681114 PECOS PAC ID: 2961467386 Enrollment ID: O20100804000784 |
News Archive
ImmunoGen, Inc. today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.
Duke Medicine researchers have shown how gene mutations may cause common forms of cartilage tumors. In a study published in the Feb. 16, 2015, issue of the Proceedings of the National Academy of Sciences, Duke researchers and their colleagues revealed that mutations in the isocitrate dehydrogenase (IDH) gene contribute to the formation of benign tumors in cartilage that can be a precursor to malignancies.
Deadly and difficult to treat, liver cancer has long resisted attempts by researchers to develop ways to prolong life and prevent recurrence.
This post on the Center for Strategic and International Studies's Commission on Smart Global Health Policy blog examines tuberculosis (TB) in South Africa, "which has the highest tuberculosis infection rate per population and accounts for 5 percent of the global TB burden."
InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.
› Verified 8 days ago
| Entity Name | Community Health Centers Of The Rutland Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780969345 PECOS PAC ID: 2961467386 Enrollment ID: O20120321000420 |
News Archive
ImmunoGen, Inc. today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.
Duke Medicine researchers have shown how gene mutations may cause common forms of cartilage tumors. In a study published in the Feb. 16, 2015, issue of the Proceedings of the National Academy of Sciences, Duke researchers and their colleagues revealed that mutations in the isocitrate dehydrogenase (IDH) gene contribute to the formation of benign tumors in cartilage that can be a precursor to malignancies.
Deadly and difficult to treat, liver cancer has long resisted attempts by researchers to develop ways to prolong life and prevent recurrence.
This post on the Center for Strategic and International Studies's Commission on Smart Global Health Policy blog examines tuberculosis (TB) in South Africa, "which has the highest tuberculosis infection rate per population and accounts for 5 percent of the global TB burden."
InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kim Kurak, DO 71 Allen St, Ste 403, Rutland, VT 05701-4570 Ph: (802) 772-4414 | Kim Kurak, DO 420 Grove St, Brandon, VT 05733-9062 Ph: (802) 247-6305 |
News Archive
ImmunoGen, Inc. today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.
Duke Medicine researchers have shown how gene mutations may cause common forms of cartilage tumors. In a study published in the Feb. 16, 2015, issue of the Proceedings of the National Academy of Sciences, Duke researchers and their colleagues revealed that mutations in the isocitrate dehydrogenase (IDH) gene contribute to the formation of benign tumors in cartilage that can be a precursor to malignancies.
Deadly and difficult to treat, liver cancer has long resisted attempts by researchers to develop ways to prolong life and prevent recurrence.
This post on the Center for Strategic and International Studies's Commission on Smart Global Health Policy blog examines tuberculosis (TB) in South Africa, "which has the highest tuberculosis infection rate per population and accounts for 5 percent of the global TB burden."
InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.
› Verified 8 days ago
Lucy Mckeon, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 61 Court Dr, Brandon, VT 05733 Phone: 802-247-3755 | |
William D Barrett, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 61 Court Dr, Brandon, VT 05733 Phone: 802-247-3755 Fax: 802-247-4560 | |
George C Fjeld, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 420 Grove St, Brandon, VT 05733 Phone: 802-247-6305 Fax: 802-247-6040 | |
Carrie C Wulfman, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 61 Court Dr, Brandon, VT 05733 Phone: 802-247-3756 Fax: 802-247-4560 |